Aixial Group Partners with Medidata to Enhance Clinical Trial Efficiency

Partnership Overview:
Aixial Group, a contract research organization (CRO), has partnered with Medidata to migrate clinical data from one of its business units onto the Medidata Platform. This collaboration aims to create a Single Source of Truth (SSOT) for clinical trial data, enhancing data management and decision-making processes.

Benefits of the Partnership:
The migration to the Medidata Platform is expected to improve patient data privacy, safety monitoring, and informed decision-making during clinical trials. It will also streamline study execution and accelerate the achievement of database locks.

Enhanced Operational Efficiency:
By consolidating clinical data onto the Medidata Platform, Aixial Group aims to enhance the skills and knowledge of its teams, providing superior service to clients and supporting studies of varying sizes, durations, and complexities.

Impact on Clinical Trials:
The partnership is designed to improve the clinical trial experience for both participants and sponsors, leveraging Medidata's solutions to expedite clinical research initiatives and deliver results faster.

Medidata's Expertise:
Medidata, a Dassault Systèmes brand, has extensive experience in clinical trial solutions, having supported over 34,000 trials and impacting 10 million patients. Its platform is recognized for enhancing patient experiences and accelerating the market introduction of therapies.